Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

Searching Tips!

You can use a suffix operator (*) as the placeholder for end of a term. The query must start with at least one alphanumeric character before the suffix operator. E.g., Rifam* will get you “Rifampicin” and “Rifampin”. For more advanced searching tips click here.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 149 Matches

Lopinavir&Ritonavir_V13R2_USFDA_20190719

Model Files Publication

Compound files from publication: Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir Wagner, C., Zhao, P., Arya, V., Mullick, C., Struble, K. and Au, S (2017). https://doi.org/10.1002/jcph.936 /PMID#: 28569994 The compound file is the final model used for simulations in combination with ritonavir (submitted to repository referencing the same article). Correction: Ritonavir's pKa 2 should be 2.6, reported in Supp. Table 1 was 2.8 https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/jcph.936

Search Score: 1

Oseltamivir_Carboxylate_V12R1_USFDA_20150709

Model Files Publication

Metabolite of oseltamivir. Information can be found in Table 1 and supplemental file of the publication. Table 1. also in supplemental file. Correction: Molecular weight should be 284 g/mol (in cmp file). Table 1 mistakenly listed MW of prodrug oseltamivir. Correction will be submitted to journal. The submitted cmp file has custom dosing. Oral dosing should be selected and dose should be adjusted according to MW differences between OC and prodrug oseltamivir to allow OC PK to be simulated when prodrug is given intravenously.

Search Score: 1

Clopidogrel_RES_V21R1_Simcyp_20220720

Model Files Publication

The V21 RES-Clopidogrel model has been developed as an inhibitor of CYP2C8, CYP3A4 and OATP1B1. Compound file and performance summary in V21 are available, as well as a workspace containing the metabolite.

Search Score: 1

Sulfasalazine_RES_V18R1_Simcyp_20190118

Model Files Publication

Simcyp developed sulfasalazine compound file. Compound summary included. This was developed as a research file and its current status and limitations are outlined in summary document.

Search Score: 1

Search the PBPK Model Repository

Searching Tips!

Lopinavir&Ritonavir_V13R2_USFDA_20190719

Oseltamivir_Carboxylate_V12R1_USFDA_20150709

Clopidogrel_RES_V21R1_Simcyp_20220720

Sulfasalazine_RES_V18R1_Simcyp_20190118

Your Privacy